As of May 2024 Anavex Life Sciences has a market cap of $0.33 Billion. This makes Anavex Life Sciences the world's 6442th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $0.33 B | -55.64% |
2023 | $0.76 B | 5.86% |
2022 | $0.72 B | -45.23% |
2021 | $1.31 B | 264.53% |
2020 | $0.36 B | 144.59% |
2019 | $0.14 B | 102.12% |
2018 | $73.14 M | -48.63% |
2017 | $0.14 B | -9.22% |
2016 | $0.15 B | -18.74% |
2015 | $0.19 B | 1803.78% |
2014 | $10.13 M | 7.75% |
2013 | $9.41 M | -60.61% |
2012 | $23.89 M | -27.97% |
2011 | $33.16 M | -63.84% |
2010 | $91.71 M | 103% |
2009 | $45.17 M | -12.19% |
2008 | $51.45 M | -50.31% |
2007 | $0.10 B | 99.76% |
2006 | $51.84 M |
On May 27th, 2024 the market cap of Anavex Life Sciences was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Ligand Pharmaceuticals LGND | $1.53 B | 351.86% | ๐บ๐ธ USA |
Corcept Therapeutics
CORT | $3.18 B | 838.27% | ๐บ๐ธ USA |
Palatin Technologies PTN | $30.98 M | -90.86% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $1.23 B | 264.98% | ๐บ๐ธ USA |